Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial, published today in The Lancet, were first presented at the European Society for Medical Oncology (ESMO) Congress 2022.
Neoadjuvant immunotherapy improves outlook in high-risk melanoma
Patients with high-risk melanoma who received the immunotherapy drug pembrolizumab both before and after surgery to remove cancerous tissue...
Dual-targeting CAR NK cells can prevent cell dysfunction and tumor escape
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to engineering natural killer (NK) cells with...
Dietary supplementation may improve antibiotic-induced GVHD following stem cell transplants
Researchers at The University of Texas MD Anderson Cancer Center have identified a specific gut bacterium involved in the progression of graft-versus-host disease (GVHD) after antibiotic treatment of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and discovered that nutritional supplementation can prevent antibiotic-induced GVHD in preclinical models, according to a study published today in Cell.
Researchers led...
MD Anderson Research Highlights for September 28, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson celebrates World Cancer Research Day
The University of Texas MD Anderson Cancer Center again supports World Cancer Research Day, Sept. 24, and its goals to highlight...
CPRIT awards $2.5 million to support MD Anderson cancer research
The University of Texas MD Anderson Cancer Center was awarded $2.5 million today from the Cancer Prevention and Research Institute of Texas...
MD Anderson Research Highlights for September 14, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson and Radiopharm Theranostics launch joint venture to develop novel radiopharmaceuticals
The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics today announced the launch of Radiopharm Ventures, LLC, a joint...
Tumor-infiltrating B cells and plasma cells influence early-stage lung cancer biology, immunotherapy responses
Through extensive single-cell analysis, researchers at The University of Texas MD Anderson Cancer Center have created a spatial map of tumor-infiltrating...
RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in...
Immunotherapy before surgery induces complete response in more than half of patients with common skin cancer in international study
ABSTRACT 789O
In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3%...
HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment
ABSTRACT 2170O
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2...
MD Anderson Research Highlights: ESMO 2022 Special Edition
ABSTRACTS 735MO, 316O, 1MO, 1493MO, 457MO, 283MO, LBA68, 785O
The University of...
MD Anderson and Virogin Biotech announce strategic collaboration to accelerate oncolytic virus research and development for treating advanced cancers
The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development...
Swathi Arur named Emerging Leader in Health and Medicine Scholar by National Academy of Medicine
Swathi Arur, Ph.D., professor and deputy chair of Genetics at The University of Texas MD Anderson Cancer Center, has been selected as one...